| DC Field | Value | Language |
|---|
| dc.contributor.author | Vostokova, N. V. | - |
| dc.contributor.author | Trakhtenberg, Y. A. | - |
| dc.contributor.author | Smolyarchuk, E. A. | - |
| dc.contributor.author | Svistunov, A. A. | - |
| dc.contributor.author | Serebrova, S. Y. | - |
| dc.date.accessioned | 2022-04-27T17:06:56Z | - |
| dc.date.available | 2022-04-27T17:06:56Z | - |
| dc.date.issued | 2017 | - |
| dc.identifier.citation | Adaptive design in clinical development of next-in-class drugs / N.V. Vostokova [et al.] // Research result. Pharmacology and clinical pharmacology. - 2017. - Vol. 3, № 3.- P. 121-134. - Doi: 10.18413/2313-8971-2017-3-3-121-134. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46427 | - |
| dc.description.abstract | The study objective was to assess the perspectives of the adaptive design methods in clinical development of the next-in-class drugs of different pharmacological groups including hypoglycemic agents, anticoagulants and anti-HIV drugs | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | clinical trials | ru |
| dc.subject | adaptive design | ru |
| dc.subject | next-in-class drugs | ru |
| dc.subject | non-inferiority | ru |
| dc.subject | diabetes mellitus | ru |
| dc.subject | DPP-4 inhibitor | ru |
| dc.subject | factor Xa inhibitor | ru |
| dc.subject | gosogliptin | ru |
| dc.title | Adaptive design in clinical development of next-in-class drugs | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 3, № 3
|
